Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allozyne Inc.

www.allozyne.com

Latest From Smith & Nephew Endoscopy

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Cayenne Medical, which is developing an implant for anterior cruciate ligament repair; Illumasonix, which has a new hemodynamic imaging technology, and Precision Biopsy, which has an optical biopsy needle for prostate cancer.
Medical Device

Deal Statistics Quarterly, Q3 2006

In this issue, we present another installment of our quarterly review of dealmaking-for July-Spetember 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (9/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Vascular Insights LLC

Vascular Insights isn't saying much yet about its minimally invasive technology for varicose veins, other than it is designed to trigger spasms in the endothelium of the diseased vein in conjunction with the delivery of a sclerosant, a chemical irritant that will further disrupt the vessel wall. This one-two punch will cause veins to stenose very rapidly without risk to surrounding tissues, the company claims, enabling a fast, pain-free procedure in an outpatient setting
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allozyne Inc.
  • Senior Management
  • Meenu Chhabra, Pres. & CEO
    Kenneth Grabstein, PhD, CSO
  • Contact Info
  • Allozyne Inc.
    Phone: (206) 518-5700
    1600 Fairview Ave. E
    Ste. 300
    Seattle, WA 98102
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register